Ready-to-use long-acting brexpiprazole formulation
A stable, injectable brexpiprazole formulation in an aqueous suspension with crystalline brexpiprazole, polysorbate, and polyvinyl pyrrolidone addresses the need for long-acting, readily resuspendable suspensions, enhancing treatment compliance and stability for conditions like schizophrenia and depression.
Patent Information
- Application Number
- PCT/EP2026/063028
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Current brexpiprazole formulations for oral administration require frequent dosing, leading to issues with medication compliance and potential drug hiding, and there is a need for long-acting, readily resuspendable suspensions for improved treatment adherence in conditions like schizophrenia and depression.
A stable, injectable, long-acting brexpiprazole formulation in the form of an aqueous suspension, comprising crystalline brexpiprazole, polysorbate or poloxamer, and polyvinyl pyrrolidone, which is readily resuspendable and maintains stability for at least 2-12 months.
The formulation ensures uniform dosing and improved treatment compliance by providing a stable, injectable suspension that can be easily resuspended without vigorous techniques, maintaining brexpiprazole content above 90% over the specified shelf life.
Smart Images

Figure IMGF000011_0001 
Figure IMGF000011_0002 
Figure IMGF000012_0001
Abstract
Description
READY-TO-USE LONG-ACTING BREXPIPRAZOLE FORMULATION Field of the Invention
[0001] The present invention relates to the field of pharmaceutical preparations and relates to long-acting brexpiprazole formulations and to a method for preparing the same.Background Art
[0002] Brexpiprazole, a product of iteration of aripiprazole, is a second generation antischizophrenic drug. As a partial agonist for the 5-HT1A receptor and the dopamine D2 receptor, and an antagonist for the 5-HT2A receptor, brexpiprazole is clinically used for adjuvant treatment of adult schizophrenia or adult major depression. Compared with aripiprazole, brexpiprazole has lower intrinsic activity for the dopamine D2 receptor, higher binding capacity with the 5-HT1 and 5-HT2 receptors, lower extrapyramidal side effects, and lower akathisia adverse effect, and thus is a first-line drug for treating schizophrenia.
[0003] Currently marketed products of brexpiprazole are tablets for oral administration once a day and there are still many problems in clinical use. For example, schizophrenia has a relatively long course, and patients are prone to hiding drugs, missing drug taking, and the like since the currently marketed brexpiprazole tablets need to be administrated frequently. To improve the medication compliance and long-term treatment compliance of the patients, increase the effectiveness of treatment, and avoid relapse and deterioration of disease, it is of great clinical significance to develop a long-acting brexpiprazole preparation.
[0004] Pharmaceutical compositions having delayed release properties of brexpiprazole are described for example, in WC2017 / 134038A, US10624889B2, and WC2013 / 162046A. The formulations comprise crystalline forms of brexpiprazole dihydrate. Crystalline brexpiprazole having a unimodal particle size distribution is described in WO2018 / 1418886A. EP4400097A discloses a long-acting brexpiprazole preparation wherein a dried powder of brexpiprazole is used for the preparation of a suspension. B. Wu et al. discloses engineered poly(D,L-lactide-co-glycolide) (PLGA) microspheres in a composition comprising sodium carboxyl methylcellulose, Tween, and mannitol for extended release of brexpiprazole.WO2021 / 233402A, WO2023 / 083212A, and CN118787642A disclose formulations for brexpiprazole which comprise poloxamer 188 as a surfactant.
[0005] Therefore, there is still the need for long-acting brexpiprazole formulations which are readily resuspendable suspensions and can be conveniently administered as ready-to-use dosage forms.Summary of invention
[0006] It is the object of the present invention to provide a stable, injectable, long-acting brexpiprazole formulation in the form of an aqueous suspension which is readily resuspendable. The object is solved by the subject matter of the present invention.
[0007] According to the invention, there is provided a stable, injectable, long-acting formulation in the form of an aqueous suspension, comprising: crystalline forms of brexpiprazole, at least one surfactant selected from the group consisting of polysorbate and poloxamer, and polyvinyl pyrrolidone (PVP), and wherein the suspension is readily resuspendable.
[0008] In one embodiment, the surfactant is poloxamer P188, poloxamer P338, or polysorbate PS80.
[0009] In another embodiment, the polyvinyl pyrrolidone is PVP K30.
[0010] In one embodiment, the formulation has a shelf life at a temperature of 25° C of at least 2 months, or at least 3 months, or at least 6 months, or at least 12 months.
[0011] According to a specific embodiment, the formulation has a brexpiprazole drug loading dose of 25 to 300 mg / mL, 50 to 150 mg / mL, 75 to 125 mg / mL, or 100 mg / mL.
[0012] According to one embodiment, the pH of the aqueous solution is equal to or greater than 7.0, or equal to or greater than 7.5.
[0013] In one embodiment, the aqueous suspension comprises particles of brexpiprazole or of crystalline brexpiprazole.
[0014] In another embodiment, brexpiprazole or crystalline brexpiprazole particles have a particle size distribution with a DvlO of 0.1 to 5.0 pm, Dv50 of 0.3 to 10.0 pm, and Dv90 of 2.0 to 30.0 pm.
[0015] According to one embodiment, the particle size is measured by laser diffraction.
[0016] In one embodiment, the surfactant may be present in a concentration in the range of 0.1 to 50 mg / mL, or of 10 to 40 mg / mL, or of 15 to 30 mg / mL. The polyvinyl pyrrolidone may be present in a concentration in the range of 10 to 30 mg / mL, or of 10 to 20 mg / mL.
[0017] According to one embodiment, the aqueous solution further comprises an additive selected from the group consisting of a salt, a sugar, a stabilizer, a buffer, a pH adjuster, or any combination thereof.
[0018] In one embodiment, the formulation in the form of an aqueous suspension comprises an aqueous solution comprising water, poloxamer P338, polyvinyl pyrrolidone PVP K30, a crystalline form of brexpiprazole, and at least one additive selected from the group consisting of a salt, a sugar, a stabilizer, a buffer, a pH adjuster, or any combination thereof, and wherein the suspension is easily resuspendable.
[0019] According to one embodiment, the buffer may be selected from the group consisting of sodium dihydrogen phosphate, disodium phosphate, and sodium phosphate, or the like. The pH adjuster may be selected from the group consisting of hydrochloric acid, sodium hydroxide, and phosphoric acid, or the like.
[0020] A further embodiment relates to a method for producing the formulation as described herein, comprising the steps of dissolving at least one surfactant selected from the group consisting of polysorbate and poloxamer, and polyvinyl pyrrolidone in water, adding crystalline forms of brexpiprazole to obtain a suspension, placing the suspension and milling beads into a vessel, milling of the suspension, and removing the milling beads to obtain a readily resuspendable suspension.
[0021] One embodiment of the invention relates to a pharmaceutical composition comprising the formulation as described herein.
[0022] In one embodiment, the pharmaceutical composition comprising the formulation as described herein is administered by injection to a subject in need thereof.
[0023] One embodiment of the invention relates to a vial or a prefilled syringe comprising the formulation as described herein.
[0024] A further embodiment relates to the use of the formulation as described herein for the preparation of a pharmaceutical composition, or of a vial, or of a prefilled syringe.
[0025] One embodiment of the invention relates to the pharmaceutical composition, or to the vial, or to the prefilled syringe as described herein, for use in the treatment or prevention of schizophrenia, bipolar disorder, or depression.Brief description of drawings
[0026] Fig. 1 depicts an overlay of PSD data from sample #2 at the start of the study and after a storage time of two months under ambient and accelerated conditions.
[0027] Fig. 2 depicts PSD measurement overlay of center point samples (#5, #6, #7) at the start of the study and after a storage time of two months under ambient and accelerated conditions, each trace depicts an average of five individual measurements.
[0028] Fig. 3 depicts an overlay of PSD data from sample #13 at the start of the study and after a storage time of two months under ambient and accelerated conditions.
[0029] Fig. 4 depicts PSD measurement overlay of center point samples (#12, #13, #14) at the start of the study and after a storage time of two months under ambient (25° C) and accelerated (40° C) conditions, each trace depicts an average of five individual measurements.
[0030] Fig. 5 depicts exemplarily sample #15 showing a crystalline sediment with a clear supernatant after a storage time of two months under ambient and accelerated conditions.
[0031] Fig. 6 depicts an overlay of PSD data from sample #16 at the start of the study and after a storage time of two months under ambient and accelerated conditions.
[0032] Fig. 7 depicts PSD measurement overlay of center point samples (#19, #20, #21) at the start of the study and after a storage time of two months under ambient (25° C) and accelerated (40° C) conditions, each trace depicts an average of five individual measurements.
[0033] Fig. 8 depicts PSD measurement overlay of i.m. administration formulation samples (#22A, #22 B, #22C), each trace depicts an average of five individual measurements.
[0034] Fig. 9 depicts the summarized table for the mean brexpiprazole concentration of each rat blood sample.
[0035] Fig. 10 depicts mean brexpiprazole concentration of each group (A: Group 2 i.m , B: Group 3 i.m , C: Group 4 {i.m}, D: Group 5 {p.o}').Description of Embodiments
[0036] The present invention provides a stable, injectable, long-acting formulation in the form of an aqueous suspension, comprising: an aqueous solution comprising water, at least one surfactant selected from the group consisting of polysorbate and poloxamer, polyvinyl pyrrolidone, and crystalline forms of brexpiprazole. The stable, injectable, long-acting formulation is in the form of a suspension which comprises of brexpiprazole particles. The stable, injectable, long-acting formulation in the form of a suspension is readily resuspendable.
[0037] In this context, the term “stability” is understood to mean the definition developed by the Working Group for Pharmaceutical Process Engineering (APV), according to which “stability” means the quality of the medicinal product as specified until the end of the term specified by the manufacturer. The quality of the drug is determined by the active substance content and the purity, the sensoriallyperceptible, physicochemical and microbiological properties, whereby the active substance content should not fall below 90% of the declared value by the end of the term. The shelf-life shall be defined as the time period during which the content of any impurity reaches 0.5% relative to the nominal amount of the active substance.
[0038] The term “about” as used herein refers to values in the range of + / - 10% of the recited value.
[0039] Suspensions are essential pharmaceutical formulations used to deliver insoluble drugs in a liquid medium. They come in two main types: flocculated and deflocculated suspensions, each with distinct characteristics.
[0040] Flocculated suspensions contain particles that are loosely aggregated to form flocs or clusters. These flocs settle rapidly but can be easily redispersed upon shaking, preventing the formation of a hard cake at the bottom of the container. The advantage of flocculated suspensions is that they are easier to redisperse, ensuring uniform dosing.
[0041] Deflocculated suspensions, on the other hand, have individual particles that remain separate and do not form flocs. These particles settle slowly and form a dense sediment over time, which can be difficult to redisperse, leading to non-uniform dosing. While they provide a more stable suspension in terms of particle settlement, the hard sediment formed can pose challenges.
[0042] The primary difference between flocculated and deflocculated suspensions lies in their particle interaction and settling behavior. Flocculated suspensions settle quickly but are easily resuspended, whereas deflocculated suspensions settle slowly but can form a hard cake that is hard to redisperse.
[0043] Stability problems in suspensions include sedimentation, particle aggregation, and changes in particle size distribution. These issues can affect the uniformity and efficacy of the suspension. Methods to overcome these stability problems include using suspending agents like carboxymethylcellulose or xanthan gum to increase the viscosity of the medium, which slows down sedimentation. Flocculating agents such as electrolytes or surfactants can promote the formationof flocs, making the suspension easier to resuspend. Additionally, controlled particle size reduction through milling or grinding ensures uniform particle distribution and reduces settling.
[0044] The suspension according to the invention can readily be resuspended without the need for instruments or vigorous techniques.
[0045] Resuspendability may be defined as follows:Level 1 = The suspension can be resuspended with < 30 inversions of the vial. Level 2 = The suspension can be resuspended by shaking.Level 3 = The suspension can be resuspended by vortexing.Level 4 = The suspension can be resuspended by ultrasonication and vortexing.
[0046] According to one embodiment of the invention, the formulation is readily resuspendable when it corresponds to level 1 or level 2. Level 1 means that the suspension can be resuspended by repeated inversion of the vial, e.g, by holding a vial between the thumb and index finger and turning it upside down and back 30 times or less within about 30 seconds. Level 2 means the suspension can be resuspended by shaking, e.g. by holding a vial between the thumb and index finger and shaking it up and down (about 20 cm movement) for about 30 times within about 15 seconds. No additional equipment or methods are required for level 1 or level 2 resuspendability. Suspensions that require vortexing or ultrasound are not considered easily or readily resuspendable, as these more vigorous techniques are impractical for routine clinical use by health care practitioners. These methods are useful and appropriate for evaluating the quality of a suspension during development, but they do not reflect standard clinical handling.
[0047] According to one embodiment of the invention, the stable, injectable, long-acting formulation in the form of an aqueous suspension comprises crystalline forms of brexpiprazole. Solid crystalline forms of brexpiprazole are commercially available.
[0048] For example, the list of US Drug Master Files (US DMFs) published by the FDA contains about 20 entries for brexpiprazole (https: / / www.fda.gov / drugs / drug-master-files-dmfs / list-drug-master-files-dmfs).
[0049] According to one embodiment of the invention, the stable, injectable, long-acting formulation in the form of an aqueous suspension comprises at least one surfactant. The surfactant may coat the drug particles to prevent aggregation or agglomeration of API particles, assuring their resuspendability and homogeneity upon administration.
[0050] The surfactant may be a polysorbate or a poloxamer.
[0051] Polysorbates are oily liquids derived from ethoxylated sorbitan (a derivative of sorbitol) esterified with fatty acids. Examples of polysorbates are polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate), and polysorbate 80 (polyoxyethylene (20) sorbitan monooleate).
[0052] Poloxamers are nonionic triblock copolymers composed of a central hydrophobic chain of polyoxypropylene flanked by two hydrophilic chains of polyoxyethylene. Because the lengths of the polymer blocks can be customized, many different poloxamers exist that have slightly different properties. For the generic term poloxamer, these copolymers are commonly named with the letter P (for poloxamer) followed by three digits: the first two digits multiplied by 100 give the approximate molecular mass of the polyoxypropylene core, and the last digit multiplied by 10 gives the percentage polyoxyethylene content e.g., P338 = poloxamer with a polyoxypropylene molecular mass of 3.300 g / mol and an 80% polyoxyethylene content). Suitable poloxamers for use in the present invention are P124, P188, P338, and P407.
[0053] According to one embodiment of the invention the surfactant is present in a concentration of 0.1 to 50.0 mg / mL, or of about 0.5 to 50.0 mg / mL, or of about 1.0 to 50.0 mg / mL, or of about 1 to 40.0 mg / mL, or of about 1.0 to 30.0 mg / mL, or of about 1.0 to 20.0, or of about 1.0 to 10.0 mg / mL.
[0054] The stable injectable long-acting formulation of the present invention is in the form of an aqueous suspension which further comprises a polymer as a steric stabilizer to increase the viscosity of the suspension.
[0055] Known polymers in this regard are for example polyethylene glycol (PEG), carboxymethyl cellulose (CMC), and polyvinyl pyrrolidone (PVP).
[0056] PEG is also known as polyethylene oxide (PEC) or polyoxyethylene (POE), or Macrogol depending on its molecular weight. The structure of PEG is commonly expressed as H - (O-CH2-CH2)n-OH.
[0057] Carboxymethyl cellulose (CMC) is a water-soluble cellulose ether produced by the partial substitution of the cellulose hydroxyl groups with ionic hydrophilic moieties. The average number of hydroxyls in the glucose unit that has reacted is called the degree of substitution (DS) and CMCs are categorized accordingly.
[0058] PVP, also commonly called polyvidone or povidone, is a water-soluble polymer compound made from the monomer / V-vi ny I pyrrol idone. PVP is available in a range of molecular weights and related viscosities and can be selected according to the desired application properties.
[0059] Suitable PVPs for use according to the invention are PVP K-25, K-30, K-90. According to a specific embodiment, the polymer is polyvinyl pyrrolidone, specifically the polyvinyl pyrrolidone is PVP K30.
[0060] According to one embodiment of the invention the polymer is present in a concentration of 0.1 to 50.0 mg / mL, or of about 0.5 to 50.0 mg / mL, or of about 1.0 to 50.0 mg / mL, or of about 1 to 40.0 mg / mL, or of about 1.0 to 30.0 mg / mL, or of about 1.0 to 20.0, or of about 1.0 to 10.0 mg / mL. According to another embodiment of the invention the polyvinyl pyrrolidone may be present in a concentration of 0.1 to 50.0 mg / mL, or of about 0.5 to 50.0 mg / mL, or of about 1.0 to 50.0 mg / mL, or of about 1 to 40.0 mg / mL, or of about 1.0 to 30.0 mg / mL, or of about 1.0 to 20.0, or of about 1.0 to 10.0 mg / mL.
[0061] According to one embodiment of the invention, the stable, injectable, long-acting formulation exhibits a shelf-life (or in other words stability or running time) at a temperature of 25° C of at least 2 months, or of at least 3 months, or of at least 6 months, or of at least 12 months.
[0062] According to another embodiment, the stable injectable, long-acting, formulation exhibits a shelf-life at a temperature of 2 to 80C of at least 2 months,or of at least 3 months, or of at least 6 months, or of at least 12 months, or of at least 24 months. The brexpiprazole content by the end of the term may be above 90%, or above 95%, of the brexpiprazole originally added.
[0063] According to another embodiment, the stable injectable, long-acting, formulation exhibits a shelf-life at a temperature of 250C of at least 2 months, or of at least 3 months, or of at least 6 months, or of at least 12 months, or of at least 24 months. The brexpiprazole content by the end of the term may be above 90%, or above 95%, of the brexpiprazole originally added.
[0064] The shelf-life shall be defined as the time period during which the content of any impurity reaches 0.5% relative to the nominal amount of brexpiprazole. This impurity level can be reliably determined using established analytical methods such as High-Performance Liquid Chromatography with UV detection (HPLC-UV) or High-Performance Liquid Chromatography with Mass Spectrometric detection (HPLC-MS).
[0065] A further embodiment relates to the stable, injectable, long-acting formulation as described herein, wherein the formulation comprises a brexpiprazole drug loading of about 10 to 360 mg / mL, or of about 20 to 240 mg / mL, or of about 30 to 125 mg / mL, or of about 100 mg / mL.
[0066] One embodiment of the invention relates to the stable, injectable, long-acting formulation as described herein, wherein the solid crystalline particles of brexpiprazole in the suspension are milled to reduce their particle size. The brexpiprazole starting material may have a starting particle size distribution (PSD) in the range of 10-200 pm (Dv90).
[0067] The term “particle size distribution”, “PSD”, or “particle size range” are used herein synonymously. The term PSD as described herein refers to the size of particles in a solution or in a suspension and indicates the range of particle sizes present.
[0068] Dv90 as used herein means that 90% of the particles (based on volume) are smaller than or equal to the indicated size. Dv50 as used herein means that 50% of the particles (based on volume) are smaller than or equal to the indicated size.DvlO as used herein means that 10% of the particles (based on volume) are smaller than or equal to the indicated size.
[0069] According to one embodiment, the particles have a particle size distribution with a DvlO of 0.1 to 5.0 pm, a Dv50 of 0.3 to 10.0 pm, and a Dv90 of 2.0 to 30.0 pm, or a particle size distribution with a DvlO of 0.1 to 3.0 pm, a Dv50 of 0.3 to 10.0 pm, and a Dv90 of 2.0 to 30.0 pm.
[0070] The particle-size distribution (PSD) of particles dispersed in fluid, is a list of values or a mathematical function that defines the relative amount, typically by mass, of particles present according to size. Several measurement techniques are known in the art, e.g., sieve analysis, air elutriation analysis, photoanalysis, optical or electroresistance counting methods, sedimentation techniques, and laser diffraction methods. Laser diffraction analysis depends upon analysis of the "halo" of diffracted light produced when a laser beam passes through a dispersion of particles in air or in a liquid. The angle of diffraction increases as particle size decreases, so that this method is particularly good for measuring sizes between 0.1 and 3,000 / m.
[0071] The particle size distribution (PSD) may be determined via low-angle laser light scattering (LALLS) utilizing a Mastersizer 3000 by Malvern, or a suitable other machine. For this, samples are diluted 1:10 in a 0.5 % PS80 solution. Measurement of primary particles can be conducted with this method.
[0072] The term “span” as used herein describes a parameter for the assessment of granularity and size consistency when analyzing particle size and particle size distribution of a suspension. A value closer to 0 indicates a more uniform and consistent particle size distribution. The span is calculated according to the following equation:„r, D90— DwSpcm [ ] = - - -^50
[0073] The D[3,2] is the diameter of a sphere that has the same volume-to-surface area ratio as the entire particle ensemble. It is defined as:It is highly sensitive to fine particles, since small particles contribute disproportionately to the total surface area.
[0074] The D[4,3] is the center of gravity of the volume distribution. It is defined as:It is highly sensitive to coarse particles, since large particles dominate the volume (and mass) of a distribution. The larger the gap between D[3;2] and D[4;3], the broader or more skewed the distribution.
[0075] In one embodiment, a method for producing the formulation is described herein, comprising the steps of dissolving at least one surfactant selected from the group consisting of polysorbate and poloxamer, and polyvinyl pyrrolidone in water, adding crystalline forms of brexpiprazole to obtain a suspension, homogenizing the suspension in a vessel, optionally adding milling beads into a vessel, optionally milling of the suspension, and optionally removing the milling beads, wherein the method for producing the formulation yields a readily resuspendable suspension.
[0076] A further embodiment relates to the method for producing a formulation of brexpiprazole, comprising the steps of dissolving surfactant and polymer, optionally a buffer component in water for injection in a suitable vessel, adding crystalline brexpiprazole under stirring to form a suspension, adding suitable sized milling beads, milling of the suspension, and removing the milling beads. Milling may be conducted by spinning the containers in a double-rotation centrifuge e.g., Zentrimix 380R, Hettich Lab, Germany), which is the preferred method for multiple vessels of small volume. For bigger volumes, passing the suspension through a ball mill e.g. a DynoMill Multilab or a Netzsch DeltaVita mill, Willy A. Bachofen AG, Germany) is one option.
[0077] In one embodiment, milling of the particles is performed by wet-bead milling ceramic beads such as yttrium-stabilized zirconium beads may be used as milling medium. After milling, these milling beads can easily be removed by passing the milled suspension through a stainless steel sieve with a mesh size of about 0.1-1 pm depending on the bead size. Or the milled suspension is passed through a stainless steel sieve with a mesh size that is smaller than the diameter of the milling beads used. The milling beads may also be retained by separators within a ball mill. The suspension is pumped out of the mill, beads are kept inside the mill.
[0078] To reduce thermal stress caused by milling, the temperature of the milling device may be controlled by external cooling to remain in the range of 5 to 30° C, or to 5 to 250C, or 5 to 10° C during milling.
[0079] One embodiment of the invention relates to a pharmaceutical composition comprising the formulation in the form of an aqueous suspension as described herein. The pharmaceutical composition may be administered by injection to a subject in need thereof.
[0080] The pharmaceutical composition may be administered to the subject in need thereof by injection.
[0081] According to one embodiment, the present invention related to the pharmaceutical composition as described herein for use in the treatment or prevention of disorders affecting the central nervous system such as schizophrenia, bipolar disorder, or depression.
[0082] The terms “treatment”, “therapy” or “medical treatment” refer to the attempted remediation of a health problem, usually following a medical diagnosis or self-diagnosis. The terms "treatment", "treat", "treating" or “therapy” refer to intervention in an attempt to alter the natural course of the individual being treated, and treatment can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing the occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, decreasing the rate of disease progression, amelioration of the disease state, and improve prognosis.
[0083] In one embodiment, the formulation or the pharmaceutical composition may further comprise an additive such as for example a salt, a sugar, a stabilizer, a buffer, a pH adjuster, or the like.
[0084] The pH adjuster may be for example hydrochloric acid, sodium hydroxide, phosphoric acid, or the like.
[0085] In a specific embodiment, the formulation or the pharmaceutical composition described herein comprises a buffer or a buffering agent. The buffering agent allows to maintain the pH of the system in a range which improves the stability of brexpiprazole. Typically, the pH will be about 7, or in the range of 6.5 to 8.5, specifically about 7.5, or in the range of 7.0 to 8.0.
[0086] Typically, the buffering agent is present as an acid or a base and its conjugate base or acid, respectively. The concentration of buffer and the pH of the solution are advantageously chosen to give balance of solubility and stability.Examples of suitable buffers include mixtures of weak acids and alkali metal salts (e.g., sodium, potassium) of the conjugate base of weak acids such as sodium citrate and disodium hydrogen phosphate. Suitable buffers are for example citrate buffer, phosphate buffer, citrate / phosphate buffer, lactate buffer, aspartate buffer, malate buffer, ascorbate buffer, tartaric / citrate buffer, bicarbonate / hydrochloric acid buffer, acetate or acetic acid buffer, succinate buffer, glycine / hydrochloric acid buffer, glutamate buffer, arginine buffer, salicylate buffer, tris(hydroxymethyl)aminomethane buffer, or histidine buffer. In some embodiments, buffers based on amino acids may be employed. Mixtures of said buffer agents may also be used.
[0087] The buffer or a buffering agent may be for example, one of sodium dihydrogen phosphate, disodium phosphate, sodium phosphate, or the like.
[0088] The term “salt” as described herein refers to an ionic compound used as an additive or excipient added to the formulation or composition without interfering with the active ingredient or API. They are typically used to improve solubility, stability, absorption, bioavailability, distribution, and other pharmacological, pharmacokinetic, and pharmacodynamic parameters. Suitable salts are for example sodium chloride, hydrochloride, carbonate, bicarbonate, sodium phosphate, phosphates, magnesium sulfate, sulfates or sulphates, nitrates, sodium acetate, monosodium glutamate, salicylate, potassium tartrate, fumarate, citrate, disodiumEDTA, choline, components of buffers such as components based on the buffer or buffering agents already present in the pharmaceutical composition or formulation, or the like. Mixtures of said salts may also be used.
[0089] According to one embodiment, the salt may be sodium chloride or the like.
[0090] The term “sugar” as described herein refers to a saccharide such as monosaccharides, disaccharides, trisaccharides, tetrasaccharides, oligosaccharides, or polysaccharides. The term may not be considered limited in regard to the length or structural features of the saccharide used or limited regarding the scope of a specific functionality when used as an additive or excipient in the present formulation or composition. Suitable sugars are for example glucose, dextrose, mannitol, sucrose, lactose, sorbitol, xylitol, human milk oligosaccharides, starches, hydroxyethyl starch, cellulose, modified cellulose, dextran, or the like. Mixtures of said sugars may also be used.
[0091] According to one embodiment, the sugar may be any one of mannitol, sucrose, lactose, glucose, dextrose, or the like.
[0092] The materials used may be present in any form suitable for the present formulation of pharmaceutical composition. This includes, but is not limited to, hydration form (incorporation of water in the crystalline lattice of the material such as monohydrate, dihydrate, hexahydrate, or the like), crystalline form, polymorphism (solid material in more than one crystalline form), isomer, tautomer, isotope, or the like.
[0093] The pharmaceutical composition may be provided in a vial or syringe. The vial or syringe provides a unit dose which will provide an effective blood concentration of brexpiprazole for the treatment or prevention of relapse of schizophrenia, bipolar disorder, or depression, for at least one week. The unit dose provides a concentration of 10 to 360 mg brexpiprazole, or of 20 to 240 mg brexpiprazole, or 30 to 125 mg brexpiprazole.Examples
[0094] The Examples which follow are set forth to aid in the understanding of the invention but are not intended to and should not be construed to limit the scope ofthe invention in any way. The Examples do not include detailed descriptions of conventional methods. Such methods are well known to those of ordinary skill in the art.Example 1 - Sample Preparation
[0095] 20 mL of each carrier solution were prepared according to Table 1 in a volumetric flask. The volumetric flask was filled up to 90 %. pH was checked and adjusted to pH 7.5 (± 0.1), if necessary, and then filled up with WFI.Table 1 - Carrier solution.Buffer [mL, Surfactant Surfactant Polymer Polymer final# Surfactant Polymer WFI [mg / mL] [mL] [mg / mL] [mL] cone.20 mM]ad 20 1 P338 50 8 CMC 5 2 4mL ad 20 2 P338 50 8 CMC 15 6 4mL ad 20 3 P338 10 1.6 CMC 15 6 4mL ad 20 4 P338 10 1.6 CMC 5 2 4mL ad 20 5 P338 30 4.8 CMC 10 4 4mL ad 20 6 P338 30 4.8 CMC 10 4 4mL ad 20 7 P338 30 4.8 CMC 10 4 4mL ad 20 8 P338 50 8 PVP 5 2 4mL ad 20 9 P338 50 8 PVP 15 6 4mL ad 20 10 P338 10 1.6 PVP 15 6 4mL ad 20 11 P338 10 1.6 PVP 5 2 4mL ad 20 12 P338 30 4.8 PVP 20 8 4mL ad 20 13 P338 30 4.8 PVP 20 8 4mL ad 20 14 P338 30 4.8 PVP 20 8 4mLBuffer [mL, Surfactant Surfactant Polymer Polymer final# Surfactant Polymer WFI [mg / mL] [mL] [mg / mL] [mL] cone.20mM]ad 20 15 PS80 20 8 PVP 5 2 4mL ad 20 16 PS80 20 8 PVP 15 6 4mL ad 20 17 PS80 1 0.4 PVP 15 6 4mL ad 20 18 PS80 1 0.4 PVP 5 2 4mL ad 20 19 PS80 10 4 PVP 20 8 4mL ad 20 20 PS80 10 4 PVP 20 8 4mL ad 20 21 PS80 10 4 PVP 20 8 4mL
[0096] From each carrier solution 8.0 mL were drawn and 800 mg of brexpiprazole were added (800 mg brexpiprazole in 8.0 mL corresponds to 100 mg / mL brexpiprazole in final formulation). The actual amount of weighed brexpiprazole for each sample is shown in Table 2.Table 2 - Actual weighing of brexpiprazole for each formulation.# Actual API weighing [mg]1 799.522 800.543 799.514 799.935 800.116 800.377 799.648 800.509 799.7210 800.3811 799.6812 800.4013 799.4414 799.72# Actual API weighing [mg]15 799.7816 799.9917 799.9118 800.8019 800.0520 799.7721 799.58
[0097] Milling of brexpiprazole particles was performed by wet-bead milling via dual centrifugation. Therefore, 8.0 g of ceramic beads (0.3 - 0.4 mm) were weighed into 10 mL dual centrifugation tubes.
[0098] No target particle size distribution (PSD) was defined for brexpiprazole formulations, a preliminary milling test showed that a brexpiprazole suspension dispersed in a carrier solution is effectively milled to a Dv90 range of about 2 pm applying dual centrifugation for 10 minutes at 800 RPM (about 1 g sample, 1 g milling beads). The brexpiprazole crystals have PSD in the range of 13 pm (Dv90) before milling.
[0099] To reduce thermal stress caused by milling, the temperature of the dual centrifuge Zentrimix 380R is set to about 50C during milling. This means the inner surface of the centrifuge is cooled to the set temperature.
[0100] Milling parameters:- Milling speed: 800 RPM- Milling time: min. 10 minutes- Milling beads size: 0.3-0.4 mm- Milling temperature: about 50C.Example 2 - Preparation of stock solutions
[0101] Stock solutions for excipients were prepared according to Table 3.Table 3 Stabilizer stock- and final solution with exact weighing and final concentration.StockFilled to Stock cone. Low cone. High cone. Excipient weighing[mL] [mg / mL] [mg / mL] [mg / mL] [g]P338 12.50463 100 125 10 50 PVP K30 5.01889 100 50 5 15 PS80 5.01376 100 50 1 20 CMC 5.04015 100 50 5 15
[0102] 800 mg of brexpiprazole were weighed for each sample to reach a final concentration of 100 mg / mL of brexpiprazole in the samples. Compounding of the formulations was performed in 10 ml_ dual centrifuge tubes. Initially brexpiprazole and milling beads were added to the centrifuge tubes. Then the carrier solutions have been added to the centrifuge tubes. The experimental design is shown in Table 4.Table 4 - Experimental Design.# Surfactant Surfactant [%] Polymer Polymer [%]1 P338 5 CMC 0.52 P338 5 CMC 1.53 P338 1 CMC 1.54 P338 1 CMC 0.55 P338 3 CMC 16 P338 3 CMC 17 P338 3 CMC 18 P338 5 PVP 0.59 P338 5 PVP 1.510 P338 1 PVP 1.511 P338 1 PVP 0.512 P338 3 PVP 213 P338 3 PVP 214 P338 3 PVP 215 PS80 2 PVP 0.516 PS80 2 PVP 1.517 PS80 0.1 PVP 1.518 PS80 0.1 PVP 0.519 PS80 1 PVP 2# Surfactant Surfactant [%] Polymer Polymer [%]20 PS80 1 PVP 221 PS80 1 PVP 2Example 3 - Stability study set up
[0103] Test formulations and carrier solution placebos were stored at 250C and 400C in upright orientation. Timepoints and tests were defined up to 12 months as shown in Table 5.Table 5 - Stability study timetable for 25 ° C and 40 ° C.Test parameter Start 2 months 6 months 12 months Appearance X X X X Resuspendability X X X X pH X X X XPSD X X X XViscosity X - - X Osmolarity X X X XExample 4 - Combination of P338 + PVPVisual appearance
[0104] Visual appearance results P338 + PVP formulations are depicted in Table 6 At the start of the study and after a storage time of two months under ambient and accelerated conditions all suspensions appeared as a white homogeneous crystal suspension after resuspension.
[0105] After a storage time of two months (both conditions) all samples except #10 and #11 showed a white sediment with a turbid supernatant before resuspension. Sample #10 (250C) and sample #11 (250C and 400C) showed a not clearly definable white sediment with a turbid supernatant.Table 6 - Visual appearance results for P338 + PVP formulations.Time# AppearancepointTO white homogeneous crystal suspension8 T2M 25 before resuspension: white sediment with turbid supernatant after ° C resuspension: white homogeneous crystal suspensionTime# AppearancepointT2M 40 before resuspension: white sediment with turbid supernatant ° C after resuspension: white homogeneous crystal suspension TO white homogeneous crystal suspension T2M 25 before resuspension: white sediment with turbid supernatant 9 ° C after resuspension: white homogeneous crystal suspension T2M 40 before resuspension: white sediment with turbid supernatant ° C after resuspension: white homogeneous crystal suspension TO white homogeneous crystal suspension T2M 25 before resuspension: sediment not clearly definable 0 ° C after resuspension: white homogeneous crystal suspension T2M 40 before resuspension: white sediment with turbid supernatant ° C after resuspension: white homogeneous crystal suspension TO white homogeneous crystal suspension T2M 25 before resuspension: sediment not clearly definable 1 ° C after resuspension: white homogeneous crystal suspension T2M 40 before resuspension: sediment not clearly definable ° C after resuspension: white homogeneous crystal suspension TO white homogeneous crystal suspension T2M 25 before resuspension: white sediment with turbid supernatant 2 ° C after resuspension: white homogeneous crystal suspension T2M 40 before resuspension: white sediment with turbid supernatant ° C after resuspension: white homogeneous crystal suspension TO white homogeneous crystal suspension T2M 25 before resuspension: white sediment with turbid supernatant 3 ° C after resuspension: white homogeneous crystal suspension T2M 40 before resuspension: white sediment with turbid supernatant ° C after resuspension: white homogeneous crystal suspension TO white homogeneous crystal suspension T2M 25 before resuspension: white sediment with turbid supernatant 4 ° C after resuspension: white homogeneous crystal suspension T2M 40 before resuspension: white sediment with turbid supernatant ° C after resuspension: white homogeneous crystal suspensionResuspendability
[0106] Resuspendability results of P338 + PVP formulations are depicted in Table 7. At the start of the study all samples were homogenized by milling and were resuspendable via inversion (Level 1).
[0107] After a storage time of two months under ambient and accelerated conditions all samples were resuspendable by inversion (Level 1) and show comparable results to the start of the study.Table 7 - Resuspendability results for P338 + PVP formulations.# Time point Resuspendability Level Amount ATO Level 1 5 inversions - 8 T2M 25 ° C Level 1 15 inversions 10T2M 40 ° C Level 1 10 inversions 5TO Level 1 5 inversions - 9 T2M 25 ° C Level 1 6 inversions 1T2M 40 ° C Level 1 10 inversions 5TO Level 1 5 inversions - 10 T2M 25 ° C Level 1 7 inversions 2T2M 40 ° C Level 1 6 inversions 1TO Level 1 5 inversions - 11 T2M 25 ° C Level 1 5 inversions 0T2M 40 ° C Level 1 8 inversions 3TO Level 1 5 inversions - 12 T2M 25 ° C Level 1 5 inversions 0T2M 40 ° C Level 1 7 inversions 2TO Level 1 5 inversions - 13 T2M 25 ° C Level 1 5 inversions 0T2M 40 ° C Level 1 5 inversions 0TO Level 1 5 inversions - 14 T2M 25 ° C Level 1 5 inversions 0T2M 40 ° C Level 1 7 inversions 2PSD
[0108] PSD results of P338 + PVP formulations are depicted in Table 8. At the start of the study and after a storage time of two months under ambient andaccelerated conditions, all samples showed a monomodal distribution in a comparable size range. Sample #9 (high concentration of polymer and surfactant) displays a shift towards an increased particle size as fine particles disappear after a storage time of two months under accelerated conditions. Under ambient conditions after two months storage time sample #9 shows a decrease in particle size. Whether particle size is increasing or decreasing or the sample measurement is an analytical outlier must be evaluated at the next stability time point.
[0109] An exemplary graph with an overlay of PSD data from sample #13 at the start of the study and after two months storage time under ambient and accelerated conditions is given in Fig. 3.Table 8 - PSD results for P338 + PVP formulations.Dv(90)# Timepoint Dv(10) pm Dv(50) pm SpanpmTO 0.605 1.516 3.045 1.609 8 T2M 25 ° C 0.674 1.560 3.110 1.559T2M 40 ° C 0.691 1.580 3.070 1.507TO 0.584 1.567 3.176 1.654 9 T2M 25 ° C 0.585 1.490 2.980 1.607T2M 40 ° C 0.691 1.580 3.070 1.507TO 0.583 1.467 2.958 1.620 10 T2M 25 ° C 0.624 1.510 3.100 1.634T2M 40 ° C 0.658 1.530 3.000 1.533TO 0.573 1.452 2.939 1.629 11 T2M 25 ° C 0.598 1.490 2.980 1.603T2M 40 ° C 0.616 1.480 2.930 1.564TO 0.593 1.483 3.005 1.627 12 T2M 25 ° C 0.631 1.510 2.990 1.562T2M 40 ° C 0.660 1.530 2.980 1.513TO 0.621 1.506 2.997 1.577 13 T2M 25 ° C 0.642 1.530 3.010 1.553T2M 40 ° C 0.667 1.550 3.030 1.52214 TO 0.590 1.474 2.967 1.612Dv(90)# Timepoint Dv(10) pm Dv(50) pm SpanpmT2M 25 ° C 0.639 1.530 3.030 1.561T2M 40 ° C 0.670 1.550 3.050 1.534Viscosity
[0110] Viscosity results of P338 + PVP formulations are depicted in Table 9. Viscosity results show comparable data for all samples at the start of the study. The lower viscosity of sample #11 reflects the low surfactant and polymer concentration.Table 9 - Viscosity results for P338 + PVP formulations.Sample Time ViscosityID point [cP]#8 TO 4.8#9 TO 5.6#10 TO - #11 TO 1.7#12 TO - #13 TO 4.1#14 TO 3.9Assay and Purity (HPLC)
[0111] Assay of brexpiprazole and purity (chromatographic area of total impurities) results of P338 + PVP formulations are depicted in Table 10. After a storage time of two months under ambient and accelerated conditions all samples show comparable results to the start of the study. No increase in impurities was observed. Total amount of impurities < 0.05 % (= LOQ).Table 10 - Assay and purity results for P338 + PVP formulations.# Time point Assay Area [%] Purity Area [%]TO 99.95 < 0.058 T2M 25 ° C 99.98 < 0.05T2M 40 ° C 99.98 < 0.05TO 99.96 < 0.059 T2M 25 ° C 99.97 < 0.05T2M 40 ° C 99.97 < 0.05# Time point Assay Area [%] Purity Area [%]TO 99.97 < 0.0510 T2M 25 ° C 99.97 < 0.05T2M 40 ° C 99.97 < 0.05TO 99.95 < 0.0511 T2M 25 ° C 99.97 < 0.05T2M 40 ° C 99.98 < 0.05TO 99.95 < 0.0512 T2M 25 ° C 99.97 < 0.05T2M 40 ° C 99.98 < 0.05TO 99.95 < 0.0513 T2M 25 ° C 99.97 < 0.05T2M 40 ° C 99.98 < 0.05TO 99.95 < 0.0514 T2M 25 ° C 99.97 < 0.05T2M 40 ° C 99.98 < 0.05Center Point
[0112] One exemplary combination with median ingredient composition was prepared as Center Point for reproducibility testing. This formulation is prepared and measured in triplicate to confirm reproducibility of the experiments. The RSD (relative standard deviation) is calculated for the three replicate measures. RSD [%] calculation of center point sample results for formulations with a combination of P338 and PVP are depicted in Table 11. A graphical representation of the PSD overlays is given in Fig. 4. The center point samples show comparable results in all tested parameters at the start of the study and after a storage time of two months under ambient and accelerated conditions. It is important that the RSD of initial formulations is low to conclude on the repeatability of measurements of the starting material after compounding.Table 11 - RSD [%] results of center point samples (#12, #13, #14).Test parameter Time point Temperature RSD [%]pH TO - 0.38Dv (10) TO - 2.82Dv (50) TO - 1.11Dv (90) TO - 0.68Span TO - 1.58Test parameter Time point Temperature RSD [%] Assay TO - 0.00Purity TO - 16.9325 ° C 1.78pH T2M40 ° C 0.9825 ° C 0.89Dv (10) T2M40 ° C 0.7725 ° C 0.76Dv (50) T2M40 ° C 0.7525 ° C 0.66Dv (90) T2M40 ° C 1.1925 ° C 0.32Span T2M40 ° C 0.6925 ° C 0.00Assay T2M40 ° C 0.0025 ° C 0.00Purity T2M40 ° C 2.37Example 6 - Combinations of PS80 + PVPVisual appearance
[0113] Visual appearance results of PS80 + PVP formulations are depicted in Table 12. At the start of the study all suspensions appeared as a white homogeneous crystal suspension after milling.
[0114] After a storage time of two months under ambient and accelerated conditions samples, except #17 and #18, showed a yellow, crystalline sediment with a clear supernatant (see Fig. 5, exemplarily showing sample #15).Homogenization of those samples was not possible as foreign visible particles still appeared after ultrasonication and vortexing.
[0115] Samples #17 and #18 showed a not clearly definable white sediment and after resuspension samples appeared as white homogeneous crystal suspensions for all conditions.Table 12 - Appearance results for PS80 + PVP formulations.Time# AppearancepointTO white homogeneous crystal suspensionT2M 25 yellow, crystalline sediment with clear supernatant 5 ° C homogenization of the sample not possible T2M 40 yellow, crystalline sediment with clear supernatant ° C homogenization of the sample not possible TO white homogeneous crystal suspensionT2M 25 yellow, crystalline sediment with clear supernatant 6 ° C homogenization of the sample not possible T2M 40 yellow, crystalline sediment with clear supernatant ° C homogenization of the sample not possible TO white homogeneous crystal suspensionT2M 25 before resuspension: sediment not clearly definable 7 ° C after resuspension: white homogeneous crystal suspension T2M 40 before resuspension: sediment not clearly definable ° C after resuspension: white homogeneous crystal suspension TO white homogeneous crystal suspensionT2M 25 before resuspension: sediment not clearly definable 8 ° C after resuspension: white homogeneous crystal suspension T2M 40 before resuspension: sediment not clearly definable ° C after resuspension: white homogeneous crystal suspension TO white homogeneous crystal suspensionT2M 25 yellow, crystalline sediment with clear supernatant 9 ° C homogenization of the sample not possible T2M 40 yellow, crystalline sediment with clear supernatant ° C homogenization of the sample not possible TO white homogeneous crystal suspensionT2M 25 yellow, crystalline sediment with clear supernatant 0 ° C homogenization of the sample not possible T2M 40 yellow, crystalline sediment with clear supernatant ° C homogenization of the sample not possible 1 TO white homogeneous crystal suspensionTime# AppearancepointT2M 25 yellow, crystalline sediment with clear supernatant ° C homogenization of the sample not possible T2M 40 yellow, crystalline sediment with clear supernatant ° C homogenization of the sample not possibleResuspendability
[0116] Resuspendability results of PS80 + PVP formulations are depicted in Table 13. At the start of the study all samples were homogenized by milling and were resuspendable via inversion (Level 1).
[0117] After a storage time of two months under ambient and accelerated conditions 5 out of 7 samples were only resuspendable by ultrasonication (US) and vortexing (Level 4). The yellow crystalline sediment described in section
[0082] was not resuspendable. Samples #17 and #18 show comparable results to the start of the study and were resuspendable by inversion (Level 1).Table 13 - Resuspendability results for PS80 + PVP formulations.# Time point Resuspendability Level Amount ATO Level 1 5 inversions - 15 T2M 25 ° C Level 4 US +vortexing - T2M 40 ° C Level 4 US +vortexing - TO Level 1 5 inversions - US + - T2M 25 ° C Level 416 vortexingUS + - T2M 40 ° C Level 4vortexingTO Level 1 5 inversions - 17 T2M 25 ° C Level 1 10 inversions 5T2M 40 ° C Level 1 15 inversions 10TO Level 1 5 inversions - 18 T2M 25 ° C Level 1 10 inversions 5T2M 40 ° C Level 1 10 inversions 5 19 TO Level 1 5 inversions -# Time point Resuspendability Level Amount A T2M 25 ° C Level 4 US +vortexing - T2M 40 ° C Level 4 US +vortexing - TO Level 1 5 inversions - 20 T2M 25 ° C Level 4 US +vortexing - T2M 40 ° C Level 4 US +vortexing - TO Level 1 5 inversions - 21 T2M 25 ° C Level 4 US +vortexing - T2M 40 ° C Level 4 US +vortexing -PSD
[0118] PSD results of PS80 + PVP formulations are depicted in Table 14. At the start of the study all samples showed a monomodal distribution in a comparable size range. After a storage time of two months under ambient and accelerated conditions all samples showed a bimodal or multimodal distribution. Samples #17 and #18 displayed a monomodal distribution for both conditions after two months storage time. However, all sample results after two months show significantly increased PSD. The distribution shifts towards larger particle sizes and fine particles disappear.
[0119] An exemplary graph with an overlay of PSD data from sample #16 at the start of the study and after two months storage time under ambient and accelerated conditions is given in Fig. 6.Table 14 - PSD results for PS80 + PVP formulations.# Timepoint Dv(10) pm Dv(50) pm Dv(90) pm SpanTO 0.549 1.245 2.676 1.709T2M 2552.300 87.400 138.000 0.98115 ° CT2M 4047.800 85.900 139.000 1.058° CTO 0.541 1.491 3.163 1.75816 T2M 2558.600 97.900 155.000 0.980° C# Timepoint Dv(10) pm Dv(50) pm Dv(90) pm Span T2M 403.440 91.500 146.000 1.560° CTO 0.466 1.240 2.690 1.793T2M 250.475 1.160 2.580 1.81617 ° CT2M 400.670 1.610 3.050 1.477° CTO 0.477 1.203 2.658 1.813T2M 250.483 1.190 2.600 1.78218 ° CT2M 400.656 1.620 3.060 1.483° CTO 0.556 1.425 2.972 1.695T2M 2512.600 74.900 137.000 1.66519 ° CT2M 4040.700 84.600 142.000 1.197° CTO 0.573 1.436 2.937 1.646T2M 256.080 67.400 128.000 1.81520 ° CT2M 4050.100 91.100 144.000 1.032° CTO 0.562 1.426 2.937 1.666T2M 2552.100 87.500 137.000 0.97521 ° CT2M 4034.100 91.200 148.000 1.248° CViscosity
[0120] Viscosity results of PS80 + PVP formulations are depicted in Table 15. Viscosity results show comparable data for all samples at the start of the study.Table 15 - Viscosity results for PS80 + PVP formulations.Time# Viscosity [cP]point15 TO 1.616 TO 2.117 TO - 18 TO - 19 TO 1.720 TO 2.321 TO 2.3Assay and Purity (HPLC)
[0121] Assay of brexpiprazole and purity (chromatographic area of total impurities) results of PS80 + PVP formulations are depicted in Table 16. After a storage time of two months under ambient and accelerated conditions all samples, except sample #18, show comparable results to the start of the study. Formulation #18 showed an amount of 0.08 % of total impurities at the start of the study. After a storage time of two months under ambient (250C) and accelerated (400C) conditions the total amount of impurities was < 0.05 % (=LOQ) for sample #18. No increase in impurities was observed. Total amount of impurities < 0.05 % (= LOQ).Table 16 - Assay and purity results for PS80 + PVP formulations (LOQ = 0.05%).# Time point Assay Area [%] Purity Area [%]TO 99.96 < 0.0515 T2M 25 ° C 100.00 < 0.05T2M 40 ° C 99.99 < 0.05TO 99.96 < 0.0516 T2M 25 ° C 100.00 < 0.05T2M 40 ° C 99.96 < 0.05TO 99.96 < 0.0517 T2M 25 ° C 99.97 < 0.05T2M 40 ° C 99.98 < 0.05TO 99.92 0.0818 T2M 25 ° C 99.98 < 0.05T2M 40 ° C 99.98 < 0.05# Time point Assay Area [%] Purity Area [%]TO 99.97 < 0.0519 T2M 25 ° C 100.00 < 0.05T2M 40 ° C 99.96 < 0.05TO 99.96 < 0.0520 T2M 25 ° C 99.95 < 0.05T2M 40 ° C 100.00 < 0.05TO 99.96 < 0.0521 T2M 25 ° C 99.96 < 0.05T2M 40 ° C 99.99 < 0.05Center Point
[0122] One exemplary combination with median ingredient composition was prepared as Center Point for reproducibility testing. This formulation is prepared and measured in triplicate to confirm reproducibility of the experiments. The RSD (relative standard deviation) is calculated for the three replicate measures. RSD [%] calculation of PS80 and PVP center point formulations are depicted in Table 17. A graphical representation of PSD overlays is given in Fig. 7. The center point samples show comparable results in all tested parameters at the start of the study and after a storage time of two months under ambient and accelerated conditions. High RSD [%] for PSD results after storage for two months reflect the instability of the samples. It is important that the RSD of initial formulations is low to conclude on the repeatability of measurements of the starting material after compounding.Table 17 - RSD [%] results of center point samples (#19, #20, #21).Test parameter Time point Temperature RSD [%]pH TO - 0.64Dv (10) TO - 1.49Dv (50) TO - 0.44Dv (90) TO - 0.67Span TO - 1.4725 ° C 2.71pH T2M40 ° C 1.09Dv (10) T2M 25 ° C 105.5540 ° C 19.3125 ° C 13.26Dv (50) T2M40 ° C 4.2525 ° C 3.88Dv (90) T2M40 ° C 2.1125 ° C 30.17Span T2M40 ° C 9.7425 ° C 0.03Assay T2M40 ° C 0.0225 ° C 90.14Purity T2M40 ° C 129.79Example 7 - In vivo Testings
[0123] Pharmacokinetic study (PK) was performed by collecting blood samples on 11 time points over a 28 day-period after a single i.m. administration of the brexpiprazole formulations at three different PSDs (#22A, #22 B, #22C), a single dose p.o. administration of brexpiprazole (described as BREX-395 herein), and a placebo comprising the formulation of #22A-C lacking the API. Blood samples were performed at T2h, T4h, T6h, T8h, and T24hfor all groups, as well as D2, D4, D7, D14, D21, and D28for the placebo group and i.m. administration groups.Formulation
[0124] The formulation for the i.m. administration of the brexpiprazole are shown in Table 18 resulting in a dosis of 100 mg / mL in the suspension. The three formulations differ in the PSD of the brexpiprazole particles in the suspension and the measured values are summarized in Table 19, as well as Fig. 8.Table 18 - Carrier solutions for in vivo formulation.pH Surfactant Polymer Buffer Resuspendability# Surfactant Polymer WFI[mg / mL] [mg / mL] [mg / mL] Level [Amount]0.1) Sodiumad 122A P338 25 PVP 15 phosphate Level 1 [5] 7.5 mL[2.76]Sodiumad 122B P338 25 PVP 15 phosphate Level 1 [5] 7.5 mL[2.76]pH Surfactant Polymer Buffer Resuspendability# Surfactant Polymer WFI[mg / mL] [mg / mL] [mg / mL] Level [Amount]0.1) Sodiumad 122C P338 25 PVP 15 phosphate Level 1 [5] 7.5 mL[2.76]Table 19 - PSD results for in vivo formulations.# Dv(10) pm Dv(50) pm Dv(90) pm D[3;2] D[4;3] Span Placebo n.a. n.a. n.a. n.a. n.a. n.a. 22A 1.30 2.61 5.35 2.29 3.34 1.55 22B 0.43 1.36 3.10 0.93 1.58 1.96 22C 0.15 0.33 0.80 0.28 0.47 1.96 BREX- 1.30 2.61 5.35 2.29 3.34 1.55 395
[0125] #22A was not milled, whereas #22B and #22C were milled with different sizes of milling beads according to the procedure described in Example 1.
[0126] PSD was detected using low angle light scattering (LALLS). For the measurement, ca. 50 mg of API were weighed into a 15 ml_ falcon tube. Afterwards, 7 mL of a 0.5 % PS80-containing solution were pipetted to the API and the suspension was vortexed for 60 sec at 3000 rpm. The homogenous suspension was treated for 5 min in an ultrasonic bath and then left under no agitation at room temperature for 3 min. The homogenous suspension is inverted 5 times before immediate addition to the dispersing solution until the desired laser ablation (5 - 15 %).Administration
[0127] The samples were homogenized to yield the brexpiprazole suspension samples for i.m. administration. Instructions for homogenization included vigorously shaking the vial for a full 30 seconds by holding the vial between the thumb and index finger and shaking it up and down (about 20 cm movement). Suspension was checked for homogenization by inverting the vial. The presence of small air bubbles was normal. After a maximum of 15 seconds after completed homogenization, the suspension was immediately slowly drawn up using the syringe. The dose of suspension was injected no longer than 10 seconds after withdrawal.
[0128] For BREX-395, the required amount of brexpiprazole for the 30 mg / kg dose was weighed into an appropriately sized container and resuspended at a concentration of 6 mg / mL, by adding the appropriate volume of 5 % gum Arabic solution (procedure as described in H. Sasabe et al. Xenobiotica 2021, 51, 5, 590-604). The solution was stirred at room temperature until adequately suspended or until a homogenous mixture was obtained.
[0129] The vehicle used was 5 % (w / v) gum Arabic in sterile water. It was prepared by weighing the appropriate amount of gum Arabic e.g., 5 g for 100 mL of the final solution) and adding sterile water QSP 100 mL. The final formulation of BREX-395, the p.o. administration of brexpiprazole, was prepared freshly on the day of administration. Powder was weighed in advance and stored at room temperature and protected from light until preparation was made.
[0130] Fifteen male Sprague-Dawley (SD) rats, 5 weeks-old at receipt respectively, weighing around 200-224 g at the beginning of the experiments were used for the present study. For each animal, the volume of i.m. and p.o. administrations were determined based on its daily body weight.
[0131] The summary for each experimental group is shown in Table 20.Table 20 - Experimental groups summary.Groups (N) T reatment Dose / Volume administration Blood sampling time points / Route1 Placebo n.a. / 0.1 mL max / i.m. T2h> T4h, T6h, T8h, T24h, (n = 3) D2, D4, D7, D14, D21, D282 22A 30 mg*kg-1 / 0.1 mL max / i.m. "Dh, T4h, T6h, T8h, T24h, (n = 3) D2, D4, D7, D14, D21, D283 22B 30 mg*kg-1 / 0.1 mL max / i.m. T2h> T4h, T6h, T8h, T24h, (n = 3) D2, D4, D7, D14, D21, D284 22C 30 mg*kg-1 / 0.1 mL max / i.m. T2h> T4h, T6h, T8h, T24h, (n = 3) D2, D4, D7, D14, D21, D285 BREX-395 30 mg*kg-1 / 5 mL*kg-1 / p.o. "Dh, T4h, T6h, T8h, T24h(n = 3)Blood sampling and plasma preparation
[0132] After the single i.m. or p.o. administrations (To), a total of 0.2 - 0.3 mL intermediary blood sampling was performed at T2h, T4h, T6h, T8h, T24h, D2, D4, D7, D14, D21, and D28through a direct puncture into the tail vein in awake animal. In case ofdifficulty reaching the caudal vein of the tail, a little skin incision on the neck was performed to directly collect the blood from the jugular vein under anesthesia (isoflurane 4 % for induction and then 2.5 % for maintain). A subcutaneous administration of 0.9 % NaCI or Ringer’s lactate was performed after each blood collection, at a volume equal to twice the collected blood volume.
[0133] For each sample, the collected blood was immediately transferred into a lithium heparin tube of 200I for plasma preparation before centrifugated at 20° C for 10 min at 3,000g. Approximatively 75-100I of supernatants were extracted for each sample and stored at -20° C until shipment on dry ice.
[0134] The concentration of brexpiprazole was determined via HPLC using a calibration curve of brexpiprazole stock solutions and verapamil as an internal standard. The developed LC MS / MS method successfully enabled reliably extraction and quantification of brexpiprazole in rat plasma samples. The method demonstrated strong sensitivity, selectivity, and consistency, providing dependable concentration data to support the objective. Accuracy of standard samples did not exceed ± 15 % bias from nominal concentrations.Results
[0135] The concentration results of rat plasma samples for brexpiprazole for the four different groups are shown in Table 21 to 24, as well as Fig. 9 and 10.Table 21 - Results of a single i.m. administration in Group 2 (n = 3).Sampling time (h) [Mean] ng / mL ± Standard deviation 2 32.18 11.504 38.81 10.706 36.48 8.198 29.64 9.1224 22.46 10.0848 23.42 10.2696 28.15 13.51168 25.23 9.92 336 8.37 1.50 504 6.20 1.84 672 3.47 0.82Table 22 - Results of a single i.m. administration in Group 3 (n = 3).Sampling time (h) [Mean] ng / mL ± Standard deviation2 96.86 35.13 4 134.32 64.49 6 157.95 66.43 8 154.09 73.07 24 61.87 21.87 48 45.25 8.46 96 30.43 3.13 168 25.57 3.55 336 6.98 0.61 504 3.74 0.65 672 2.27 1.32Table 23 - Results of a single i.m. administration in Group 4 (n = 3).Sampling time (h) [Mean] ng / mL ± Standard deviation 2 162.72 47.08 4 180.52 12.56 6 261.96 45.62 8 270.95 73.06 24 115.51 41.15 48 66.34 34.04 96 26.75 7.60 168 18.72 2.92 336 4.08 1.36 504 2.08 1.20 672 BLQ N / ATable 24 - Results of a single p.o. administration in Group 5 (n = 3).Sampling time (h) [Mean] ng / mL ± Standard deviation 2 567.90 13.42 4 293.18 27.02 6 154.71 61.82 8 103.84 26.73 24 23.43 19.88Summary
[0136] The pharmacokinetic profiles of the four groups highlight significant differences based on administration route and formulation:i.m. administration
[0137] The three groups (2 - 4) showed slow and prolonged absorption with a Tmaxranging from 4 to 8 h, a moderate Cmaxranging from 38.8 to 158 ng / mL, and a high and sustained exposure with an AUG ranging from 8,426 to 12,621 h-ng / mL, which is considered ideal for long-lasting effects. The formulations showed a long half-life ranging from 188 to 563 h, which enables reduced dosing frequency for the given formulations.p.o. administration
[0138] The group (5) showed rapid absorption with a Tmaxof 2 h, a very high Cmaxof 568 ng / mL, and a lower overall exposure with an AUG of 2,555 h-ng / mL, which is due to the limited first-pass metabolism.
[0139] The results are summarized in Table 25.Table 25 - Pharmacokinetic parameters for Group 2 to 5 (n = 3).Pharmacokinetic Group 2 Group 3 Group 4 Group 5 parameter ( / . / 77.) ( / . / 77.) ( / . / 77.) (p.o.) Mean Cmax[ng / mL] 39.8 158 271 568 Mean Tmax[h] 4 6 8 2 Mean AUCg^ [h-ng / mL] 8,426 11,543 12,621 2,555 Mean T1 / 2[h] 563 296 188 Noncalculable
Claims
Claims1. A stable, injectable, long-acting formulation in the form of an aqueous suspension, comprising:a. an aqueous solution comprising water, at least one surfactant selected from the group consisting of polysorbate and poloxamer, and polyvinyl pyrrolidone;b. a crystalline form of brexpiprazole; andwherein the suspension is readily resuspendable.
2. The formulation of claim 1, wherein the surfactant is poloxamer P188, poloxamer P338, or polysorbate PS80.
3. The formulation of claim 1 or 2, wherein the polyvinyl pyrrolidone is PVP K30.
4. The formulation of any one of claims 1 to 3, wherein the formulation has a shelf life at a temperature of 25° C of at least 2 months.
5. The formulation of any one of claims 1 to 4, comprising a brexpiprazole drug loading dose of 25 to 300 mg / mL, 50 to 150 mg / mL, 75 to 125 mg / mL, or 100 mg / mL.
6. The formulation of any one of claims 1 to 5, wherein the pH of the aqueous solution is equal to or greater than 7.0, or equal to or greater than 7.5.
7. The formulation of any one of claims 1 to 6, wherein the crystalline brexpiprazole has a particle size distribution with a DvlO of 0.1 to 5.0 pm, a Dv50 of 0.3 to 10.0 pm, and a Dv90 of 2.0 to 30.0 pm.
8. The formulation of claim 7, wherein the particle size is measured by laser diffraction.
9. The formulation of any one of claims 1 to 7, wherein the surfactant is present in a concentration in the range of 0.1 to 50 mg / mL, or of 10 to 40 mg / mL, or of 15 to 30 mg / mL.
10. The formulation of any one of claims 1 to 8, wherein the polyvinyl pyrrolidone is present in a concentration in the range of 10 to 30 mg / mL, or of 10 to 20 mg / mL.
11. The formulation of any one of claims 1 to 10, wherein the aqueous solution further comprises an additive selected from the group consisting of a salt, a sugar, a stabilizer, a buffer, a pH adjuster, or any combination thereof.
12. A stable, injectable, long-acting formulation in the form of an aqueous suspension, comprising:a. an aqueous solution comprising water, poloxamer P338, and PVP K30; b. a crystalline form of brexpiprazole;c. at least one additive selected from the group consisting of a salt, a sugar, a stabilizer, a buffer, a pH adjuster; andwherein the suspension which is readily resuspendable.
13. The formulation of claim 12, wherein the buffer is selected from the group consisting of sodium dihydrogen phosphate, disodium phosphate, sodium phosphate, or the like.
14. The formulation of claim 12, wherein the pH adjuster is selected from the group consisting of hydrochloric acid, sodium hydroxide, phosphoric acid, or the like.
15. A method for producing the formulation of any one of claims 1 to 14, comprising the steps:a. dissolving the at least one surfactant selected from the group consisting of polysorbate and poloxamer, and polyvinyl pyrrolidone in water;b. adding crystalline forms of brexpiprazole to obtain a suspension; c. placing the suspension and milling beads into a vessel;d. milling of the suspension;e. removing the milling beads; andf. obtaining a readily resuspendable suspension.
16. A pharmaceutical composition comprising the formulation of any one of claims 1 to 14.
17. The pharmaceutical composition of claim 16, wherein the composition is administered by injection to a subject in need thereof.
18. A vial or a prefilled syringe comprising the formulation of any one of claims 1 to 14, or the pharmaceutical composition of claim 16.
19. Use of the formulation of any one of claims 1 to 14 for the preparation of the pharmaceutical composition of claim 16, or the vial or prefilled syringe of claim 18.
20. The formulation of any one of claims 1 to 14, the pharmaceutical composition of claim 16, or the vial or prefilled syringe of claim 18, for use in the treatment or prevention of schizophrenia, bipolar disorder, or depression.
